We then applied the MQDL protocol to determine if the c-Met cell signaling pathway and EMT are activated in a castration-resistant prostate cancer (CRPC) animal model and in clinical prostate cancer specimens obtained from patients with high Gleason scores and bone metastasis. The gene discussed is MET; the disease is prostate cancer.